Komori
Nagase & (8012) · FactFirst stated

FY2019 Capital Investment of ¥10.612 Billion and 林原’s New Pullulan and Enzyme Building

First written in FY2019. . Latest entry: FY2019.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Construction of the pullulan and enzyme building at Hayashibara's Okayama No. 2 PlantA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019First statedAnnual report

    「During the current consolidated fiscal year, the company made total capital expenditures of ¥10.61 billion, including intangible assets, centered on ¥2.11 billion in capital expenditures related to the new pullulan and enzyme building at the Okayama No. 2 Plant of 株式会社林原 in the Lifestyle-related segment.」

    In FY2019, total capital expenditures were ¥10.612 billion, including ¥2.11 billion invested in a new pullulan and enzyme production building at Hayashibara's Okayama No. 2 Plant. Construction of the pullulan and other production facilities at Hayashibara's No. 2 Plant was scheduled for completion in September 2020, after which capacity was expected to increase by approximately 15%.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Nagase &'s next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
FY2019 Capital Investment of ¥10.612 Billion and 林原’s New Pullulan and Enzyme Building | NAGASE & CO.,LTD. (8012) | Komori